doi: 10.3389/fcdhc.2026.1772391 Received 20 December 2025 Revised 15 March 2026 Accepted 16 March 2026 Published 10 April 2026 Volume 7 - 2026 Edited by Arrigo Francesco Giuseppe Cicero, University of Bologna, Italy Reviewed by Alessando Mattina, IRRCS ISMETT/UPMC Italy, Italy Updates Copyright 2026 Jdrasek, Lisowska and Czupryniak
These 3.8 million met the clinical criteria for the Bridge program, did not have a diagnosis of type 2 diabetes, sleep apnea or MASH, did not have a GLP-1 Part D covered prescription in 2023 and "could be eligible for the Medicare GLP-1 Bridge, assuming no changes in diagnosis or GLP-1 use in Part D in 2026," the report added
This study was the first genetic evaluation of melanomas and their adjacent precursors
Add strength training twice weekly to preserve muscle mass during weight loss
MTC, medullary thyroid cancer